Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 376 to 390 of 1136 results for pain

  1. Superficial venous arterialisation for chronic limb threatening ischaemia (IPG736)

    Evidence-based recommendations on superficial venous arterialisation for chronic limb threatening ischaemia in adults. This involves joining an artery in the lower leg to a large vein to divert blood flow through the vein towards the foot, bypassing the blocked arteries.

  2. Electrotherapy for the treatment of haemorrhoids (IPG525)

    Evidence-based recommendations on electrotherapy for treating grade I to III haemorrhoids in adults. This involves using electric current to shrink the haemorrhoids.

  3. Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult (MIB53)

    NICE has developed a medtech innovation briefing (MIB) on the Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .

  4. Radiofrequency ablation for palliation of painful spinal metastases (IPG758)

    Evidence-based recommendations on radiofrequency ablation for palliation of painful spinal metastases. This involves inserting a needle-like probe containing an electrode into the spinal metastases. This produces an electrical current that aims to relieve pain and other symptoms.

  5. Radiofrequency ablation of varicose veins (IPG8)

    Evidence-based recommendations on radiofrequency ablation of varicose veins. This involves using radiofrequency energy to heat the wall of the vein so that it collapses.

  6. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.

  7. Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

    Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.

  8. Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.

  9. Single-step scaffold insertion for repairing symptomatic chondral knee defects (IPG793)

    Evidence-based recommendations on single-step scaffold insertion for repairing symptomatic chondral knee defects. This involves inserting a scaffold into the damaged area of the knee to support regrowth and repair of the cartilage.

  10. Tonsillectomy using ultrasonic scalpel (IPG178)

    Evidence-based recommendations on tonsillectomy using ultrasonic scalpel. This involves using high-energy waves to cut the tonsils out and stop the bleeding at the same time.

  11. Minimally invasive video-assisted thyroidectomy (IPG499)

    Evidence-based recommendations on minimally invasive video-assisted thyroidectomy. This involves inserting instruments through a small cut (keyhole surgery) to remove part or all of the gland.

  12. Inotersen for treating hereditary transthyretin amyloidosis (HST9)

    Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis.

  13. Osteoporosis: bone sparing agents (75 years and over) (IND92)

    This indicator covers the percentage of patients aged 75 or over with a fragility fracture on or after 1 April 2012, who are currently treated with an appropriate bone-sparing agent. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM31

  14. Osteoporosis: bone sparing agents (50-74 years) (IND91)

    This indicator covers the percentage of patients aged 50 or over and who have not attained the age of 75, with a record of a fragility fracture on or after 1 April 2012, in whom osteoporosis is confirmed on DXA scan, who are currently treated with an appropriate bone-sparing agent. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM30

  15. Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.